Abstract View: 70


Recent Progress in Development of Polo-Like Kinase 1 Inhibitors: Efforts So Far

Ramesh L. Sawant* ORCID logo, Jyoti B. Wadekar, Rushikesh D. Ukirde, Ganesh D. Barkade ORCID logo


Polo-like kinase 1(Plk1) plays an important role in the inhibition of cell proliferation and which is come under the family of serine/threonine-protein kinase. Which is a highly specific target for cancer therapy. In some clinical studies, Plk1 has been identified as a target for cancer. Currently, so many scientists are working on the development of the Plk1 inhibitors and so many scientists and researchers thinking about working on it. Recent strategy for Plk1 inhibition is the development of small molecule inhibitors which will inhibit the Plk1 through the ATP-binding site of the Plk. Now new generation Plk1 inhibitors being tested clinically which are targeting polo box domain. This review highlights the recent progress made in the development of Plk1 inhibitors as anticancer agents.
Keywords: Kinase domain, Polo-like kinase 1, Plk1, Polo box domain, Patents, Small molecule inhibitors
First Name
Last Name
Email Address
Security code

Abstract View: 59

Your browser does not support the canvas element.

PDF Download: 0

Your browser does not support the canvas element.

Submitted: 23 Sep 2020
Revision: 15 Apr 2021
Accepted: 15 Apr 2021
ePublished: 24 Apr 2021
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)